mogamulizumab at a glance
Medicine class
Humanised anti-CCR4 monoclonal antibody
Licensed use
Previously treated mycosis fungoides or Sézary syndrome in adults
Administration
Diluted and given slowly into a vein by a cancer-care team
Important risks
Infusion reactions, skin reactions and serious infections
What is mogamulizumab used for?
Mogamulizumab is licensed for adults who have already received systemic treatment for either of the following cutaneous T-cell lymphomas:
Mycosis fungoides
Sézary syndrome
How does mogamulizumab work?
Mogamulizumab binds to CCR4, a receptor found on some malignant T cells. This marks CCR4-bearing cells for removal by the immune system, reducing the targeted cell population in the skin, blood and other affected tissues.
mogamulizumab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 4 mg/mL
How to take mogamulizumab
Mogamulizumab is not taken at home. A healthcare professional dilutes the concentrate and gives it as a slow intravenous infusion in a setting equipped to manage infusion reactions.
Tell the team promptly about itching, flushing, chills, dizziness, breathing difficulty or other new symptoms during or after an infusion.
Do not shake, mix with other medicines or administer through the same intravenous line as another medicine.
The product is for intravenous infusion only, not injection into a muscle or under the skin.
mogamulizumab side effects
Common or expected effects
- Infusion-related reactions
- Rash or drug eruption
- Infections
- Diarrhoea, constipation, nausea or sore mouth
- Fatigue, fever, headache or swollen ankles and legs
- Reduced red cells, white cells or platelets
- Changes in liver tests or underactive thyroid
Get urgent medical advice
- Severe infusion reaction or anaphylaxis
- Serious infection, including pneumonia, cellulitis or sepsis
- Severe blistering or peeling skin reaction
- Colitis causing watery diarrhoea or significant abdominal pain
- Tumour lysis syndrome
- Serious complications following a later donor stem-cell transplant
mogamulizumab in pregnancy
Human pregnancy data are unavailable, and mogamulizumab can cross the placenta. Product information advises avoiding it during pregnancy as a precaution and using effective contraception during treatment and for the specified period afterwards. Pregnancy or pregnancy plans require discussion with the specialist team.
mogamulizumab while breastfeeding
It is unknown whether mogamulizumab enters human milk. A risk to a newborn cannot be excluded during the first days after birth; later breastfeeding may be considered if treatment is clinically needed. The oncology and maternity or infant-care teams should assess this together.
mogamulizumab interactions
Formal interaction studies have not been performed. The full medicine list, including non-prescription and complementary products, should be reviewed by the treating team.
Systemic immunosuppressive or immune-modulating medicines
Concurrent use may further increase the risk of serious infection or viral reactivation; combinations require specialist assessment.
Other systemic treatments for mycosis fungoides or Sézary syndrome
Safety in combination has not been established, and the product information does not recommend routine combination because of infection risk.
Common questions about mogamulizumab
Answers are fully visible for fast scanning and source review.
What cancers is mogamulizumab used to treat?
It is licensed for adults with mycosis fungoides or Sézary syndrome who have previously received systemic treatment.
Is mogamulizumab chemotherapy or immunotherapy?
It is a targeted monoclonal antibody treatment rather than conventional cytotoxic chemotherapy.
How is mogamulizumab given?
A healthcare professional dilutes it and administers it slowly through a vein in a supervised clinical setting.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.